메뉴 건너뛰기
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Volumn 2, Issue 4, 2001, Pages 19-22
Slowing down ALS ™ is this good or bad?
Author keywords

Als Cost Effectiveness Therapy Quality Of Life
Indexed keywords

GABAPENTIN; PLACEBO; RILUZOLE; SOMATOMEDIN C;
EID: 0035008046     PISSN: 14660822     EISSN: 1471180x     Source Type: Journal    
DOI: 10.1080/146608201300079373-1     Document Type: Article
Times cited : (1)
References (7)
  • 1
    • 0029977337 scopus 로고    scopus 로고
    • Amyotrophic Lateral Sclerosis Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
    • Lacomblez L., Bensimon G., Leigh P.N., et al, for the Amyotrophic Lateral Sclerosis Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431
    • (1996) Lancet , vol.347 , pp. 1425-1431
    • Lacomblez, L.1    Bensimon, G.2    Leigh, P.N.3
  • 2
    • 0031944832 scopus 로고    scopus 로고
    • An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
    • Riviere M., Meininger V., Zeisser P., et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526-528
    • (1998) Arch Neurol , vol.55 , pp. 526-528
    • Riviere, M.1    Meininger, V.2    Zeisser, P.3
  • 3
    • 0032429461 scopus 로고    scopus 로고
    • Economic burden of amyotrophic lateral sclerosis in the United Kingdom
    • Munsat, T.L., Riviere M., Swash M., et al. Economic burden of amyotrophic lateral sclerosis in the United Kingdom. J Med Econ 1998; 1: 235-245
    • (1998) J Med Econ , vol.1 , pp. 235-245
    • Munsat, T.L.1    Riviere, M.2    Swash, M.3
  • 4
    • 0030781197 scopus 로고    scopus 로고
    • Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis
    • Ginsberg G.M., Lev B. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics 1997; 12: 578-584
    • (1997) Pharmacoeconomics , vol.12 , pp. 578-584
    • Ginsberg, G.M.1    Lev, B.2
  • 5
    • 0032588644 scopus 로고    scopus 로고
    • Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS
    • Ackerman S.J., Sullivan E.M., Beursterien K.M., et al. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics 1999; 15: 179-195
    • (1999) Pharmacoeconomics , vol.15 , pp. 179-195
    • Ackerman, S.J.1    Sullivan, E.M.2    Beursterien, K.M.3
  • 6
    • 0032937575 scopus 로고    scopus 로고
    • Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis
    • Tavakoli M., Davis H.T.O., Malck M. Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis. J Med Econ 1999; 2: 1-14
    • (1999) J Med Econ , vol.2 , pp. 1-14
    • Tavakoli, M.1    Davis, H.T.O.2    Malck, M.3
  • 7
    • 10544254257 scopus 로고    scopus 로고
    • Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group
    • Miller R.G., Moore D., Young L.A., et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Neurology 1996; 46: 1383-1388
    • (1996) Neurology , vol.46 , pp. 1383-1388
    • Miller, R.G.1    Moore, D.2    Young, L.A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.